Effects of feeding frequency and exogenous somatotropin on lipolysis, hormone profiles, and milk production in dairy cows

Effects of feeding frequency and exogenous bovine somatotropin on lactational performance and hormone profiles were examined with 12 multiparous Holstein cows. At 45 d postpartum, cows were assigned to one of two feeding systems. Concentrates were offered in two equal portions at 0800 and 1600 h or in 12 equal portions at 2-h intervals. Chopped alfalfa hay (2.6 kg/d) and barley silage (ad libitum) were fed at 0900 and 1500 h. At 136 d postpartum, cows within each feeding frequency were assigned in a single crossover design to injection of 30 mg of bST/d or solubilization vehicle. Feeding frequency did not influence any of the parameters measured nor did bST interact with feeding frequency. Somatotropin injection increased daily milk yield of cows by 4.4 kg and concentrations of fat and lactose in milk. Protein concentration and fatty acid composition of milk were not influenced by bST injection. Average plasma somatotropin concentrations were elevated threefold, peak concentrations were increased sevenfold, and concentrations at 48 h postinjection were 1.5 times control values. Plasma insulin concentrations were decreased by bST treatment. Results indicate that responses to short-term bST injection are not influenced by feeding frequency.     

Long-term evaluation of a prolonged-release formulation of N-methionyl bovine somatotropin in lactating dairy cows

Eighty Holstein cows (first, second, or third lactation) were used to evaluate the efficacy of a prolonged-release formulation for sometribove (n-methionyl bovine somatotropin). Cows were fed ad libitum a complete mixed diet and milked twice daily. Cows were allocated randomly by parity to two treatment groups receiving 500 mg sometribove in a prolonged release formulation or excipient at 14-d intervals starting at 60 +/- 3 d postpartum and continuing for 36 wk. Treatment with sometribove increased FCM yield to a similar extent (11.4%, +3.1 kg/d) in primiparous and multiparous animals. Milk content of lactose, fat, ash, and Ca was not affected, but protein and phosphorous were slightly greater (less than 5%) in milk from sometribove-treated cows. Within a 14-d injection interval, animals treated with sometribove displayed a cyclic pattern in milk yield, but a similar pattern was not evident in feed intake.     

Influence of bovine somatotropin on the composition and manufacturing properties of milk.

Three studies (84, 140, and 200 d) were performed to examine the effect of injecting dairy cows with various doses (0, 320, 640, or 960 mg/28 d; 0 or 640 mg/28 d; 0, 320 mg/14 d, or 320 or 640 mg/28 d) of bST on milk production, composition, and manufacturing properties. Mean bST response among studies on milk production varied from 0 (trial 1) to 7.3% (trial 2) and from 8.5 to 14.2% (trial 3) in relation to feeding conditions. Neither milk fat nor protein percentages in milk at time of maximum response were affected by the use of bST. Distribution of casein and protein in the whey was not affected by the treatments at any time. The nature of fatty acids varied more with time after injection than with bST doses. Neither coagulation time, standard curd firmness, nor soft or pressed cheese yields were affected by the treatments.     

Lactational response of Jersey cows to bovine somatotropin administered daily or in a sustained-release formulation.

Twenty-four Jersey cows were administered either 0 or 15.5 mg of bST/d or 310 mg of bST/14 d to determine the effect on milk yield, milk composition, feed intake, and body weight. Administration of bST was from wk 14 through 42 postpartum. Cows were housed in a tie-stall barn and fed for ad libitum intake a TMR adjusted to one of two energy protein densities according to milk yield. Milk yield of cows administered bST daily or by sustained-released vehicle increased 27.6 and 24.7%, respectively, over that of control cows; FCM increased by 30.3 and 26.7%. Percentages of fat and protein in milk were unaffected by bST treatment. Dry matter intake of cows administered bST was greater than that of control cows, whether expressed as kilograms per day or as a percentage of body weight. Apparent efficiency of yield increased in cows administered bST. No significant change in body weight occurred; however, cows administered bST had lower body condition scores at 42 wk postpartum. This trial demonstrated comparable effects of bST on lactational performance when administered daily or in a 14-d sustained-release vehicle.     

Milk production in lactating buffalo receiving recombinantly produced bovine somatotropin

Thirty healthy Murrah buffalo (Bubalus bubalis) in their second to fourth lactations were selected from the herd at the National Dairy Research Institute, Karnal, Haryana, India, for use in a 35-d study to determine the effects of recombinantly produced bovine somatotropin on milk production, milk composition, and dry matter intake. Treatments were daily injections of 0, 25, or 50 mg somatotropin per animal for 14 d. All buffalo consumed green chopped fodder ad libitum plus a predetermined quantity of concentrate mixture to each animal, based on individual milk production during the 14-d pretreatment period. The quantity of concentrate mixture fed to each buffalo was not altered during the study. Net increase in milk volume for groups receiving 25 and 30 mg somatotropin was 16.8 and 29.5% over controls. Milk composition, DM intake, and body weights were not affected by treatment.     

Effects of recombinant bovine somatotropin on milk production, body composition, and physiological parameters

Twenty-eight multiparous Holstein cows were utilized to determine effects of long-term administration of recombinant bovine somatotropin on lactational performance, body condition, body composition, hormones, blood constituents, and physiological parameters. Treatments were 0 (control), 10.3, 20.6, and 41.2 mg recombinant bovine somatotropin administered daily as subcutaneous injections beginning 4 to 5 wk postpartum and continuing for 38 wk. A total mixed diet of 28% corn silage, 22% alfalfa hay cubes, and 50% corn-soybean meal-based grain mixture was fed. Fat-corrected milk yields were increased 12 to 25% for cows treated with somatotropin as compared with controls (29.9 kg/d). Milk composition was similar among treatments. Cows receiving somatotropin consumed 4 to 10% more feed and were 11 to 17% more efficient than controls for conversion of feed to milk. Body weight changes were not significantly different among treatments, but cows receiving somatotropin gained 4 to 10% less weight than controls. Body fat (kg) of cows receiving 20.6 and 41.2 mg/d was less than that of cows receiving 10.3 mg/d or no somatotropin. Estimated weights of body protein and mineral, most blood constituents, respiratory rates, and body temperature were not affected by somatotropin administration. Plasma fatty acids were elevated and hematocrit values were reduced. Plasma insulin, serum somatotropin, and heart rate increased concurrently with somatotropin administration.     

Effects of bovine somatotropin on milk yield and composition, body weight, and condition score of Holstein and Jersey cows

Forty cows (20 Holstein, 20 Jersey) were administered 0, 5, 10, 15, or 20 mg of recombinantly derived bST daily to determine the effect on milk yield, milk composition, body weight, and body condition score. Administration of bST was from 75 +/- 7 d through 305 d postpartum. A total mixed diet of 45% corn silage and 55% of a concentrate mixture (dry basis) was provided for ad libitum intake. Milk yield of Holstein and Jersey cows administered 20 mg of bST increased 25.3 and 22.8%, respectively, over controls. Fat-corrected milk from Holsteins and Jerseys that were administered 20 mg of somatotropin increased 32.2 and 18.7% over controls, but Jersey response was greatest when 15 mg of bST were administered (27.1% over controls). Dry matter intake of the 20 mg bST group was 13.5% greater than DM intake of controls. Apparent efficiency of production increased linearly with increasing somatotropin. There was no significant change in body weight, but body condition score declined linearly with increasing somatotropin. Most milk composition measures were unaffected by somatotropin. Jersey and Holstein milk yield increased quadratically and linearly, respectively, with somatotropin dose.     

Effect of exogenous bovine somatotropin on mammary lipid metabolism and milk yield in lactating dairy cows

Eight lactating Holstein cows were used to study the effect of bovine somatotropin on mammary lipid metabolism, milk production, and milk composition. Eight cows were injected with either excipient (n = 4) or 50 IU somatotropin/d (n = 4). A 2-wk adjustment period preceded a 10-d period when treatments were administered. On d 9, serial blood samples were collected from 2 to 5 h post-injection to determine concentrations of somatotropin and metabolites in plasma. Mammary tissue biopsies were obtained 2 to 3 h after a.m. milking on d 10 to determine lipoprotein lipase activity and in vitro rates of acetate incorporation into fatty acids and acetate oxidation by mammary tissue slices. Activity of lipoprotein lipase in milk and mammary tissue and rate of acetate metabolism by mammary tissue were not affected by treatment. The following means for placebo and somatotropin, respectively, were: milk production (21.5 and 24.8 kg/d), milk fat (3.8 and 4.0%), and 4% FCM (20.7 and 25.1 kg/d). Plasma concentrations of somatotropin (3.0 and 43.4 ng/ml) and free fatty acids (105.6 and 219.5 mu eq/L) were significantly elevated with somatotropin. The injection of somatotropin into lactating dairy cows did not affect the mechanisms of fatty acid synthesis or metabolism evaluated in this study.     

Bovine somatotropin dose titration in lactating dairy ewes. 3. Treatment interval.

Seventy-four lactating dairy ewes were injected with recombinant bovine somatotropin (bST; sometribove) in a sustained-release formulation. Ewes received 0, 80, 160, or 240 mg of bST/14 d at the end of 2, 4, and 6 wk postlambing, after which injections were withheld for a 28-d period. Response of milk production to bST presented a positive linear contrast and a negative quadratic contrast. After the final injection of bST (d 0), an increase in daily milk production was observed until d +9. A continuous decrease followed with milk production returned to control levels on d +11, +18, and +20, for 80, 160, and 240 mg of bST/14 d. Milk protein content decreased gradually until d +8 before it returned to control levels on d +12, +14 and +14, for 80, 160, and 240 mg of bST/14 d. Levels of bST and IGF-I in plasma presented positive and highly significant linear contrasts and negative quadratics which were significant only for bST. Relative to the evolution of milk production, the evolution of IGF-I levels in plasma was more similar than that of bST, although the correlation of each measure with milk production was high and highly significant. It was concluded that the period between successive injections should be shorter the lower the dose employed; however, a 14-d period seemed to correspond correctly for the dosages and hormone formulation tested.     

Evaluation of sometribove in a prolonged-release system in lactating dairy cows--production responses

Primiparous (n = 105) and multiparous (n = 136) Holstein cows were used to evaluate efficacy of sometribove (n-methionyl bovine somatotropin, bST) in a dose titration study. Cows were fed TMR for ad libitum intake, were milked twice daily, and were allocated randomly within parity (1 vs. 2+) to treatments of 0, 250, 500, or 750 mg bST/14 d in a prolonged-release formulation. Subcutaneous injections commenced 60 +/- 3 d postpartum and continued throughout lactation. During a standardized treatment period of 252 d, treatment with increasing dosages of bST increased 3.5% FCM yield in a dose-dependent manner for both primiparous (2.5 kg/d, 10.2%; 3.5 kg/d, 14.3%; and 5.9 kg/d, 24.1%) and multiparous cows (3.1 kg/d, 12.1%; 3.9 kg/d, 15.2%; and 6.8 kg/d, 26.5%). Milk content of fat, protein, lactose, ash, Ca and P, and SCC were not affected by treatment. Over the 252-d treatment period, voluntary intake of energy was increased in bST-treated cows such that BW gain, body condition score, and net energy balance did not differ among treatment groups. Productive efficiency (milk per unit NEL intake corrected for BW change) over the treatment period was significantly increased in a dose-dependent manner for multiparous cows (4.1, 6.8, and 11.0%). Results demonstrated that bST administered in a prolonged-release formulation was efficacious in enhancing milk production and feed efficiency.     

Lactation response of dairy cows receiving bovine somatotropin and fed rations varying in crude protein and undegradable intake protein

Our experiment evaluated lactation and metabolic responses of Holstein cows injected with somidobove (recombinant bST) and fed one of four isocaloric rations containing either 14 (low) or 17% (high) CP and undegradable intake protein of 33 (low) or 40% (high) of CP. Multiparous cows (n = 37) in early lactation, averaging 37 kg/d of milk, received somidobove (640 mg per injection) at 28-d intervals for 112 d and one of four protein rations: low-low, low-high, high-low, and high-high. Nine other multiparous controls were fed low-low ration with no somidobove. On the low-low ration, somidobove significantly increased milk yield by 2.3 kg/d, but not 3.5% FCM (1.7 kg/d), intakes of DM or CP, or milk composition. Milk and 3.5% FCM increased by 1.7 and 2.1 kg/d in cows fed high undegradable intake protein but there was no effect on milk composition, BW, or DM intake. Ration CP had no effect on production variables in cows receiving somidobove. Serum urea was higher in cows fed high CP rations; undegradable intake protein was without effect. Plasma leucine was higher in cows fed high undegradable intake protein. Administration of somidobove to cows fed low-low rations reduced plasma methionine, serum albumin, hemoglobin, and albumin:globulin ratio. Milk production of high producing dairy cows receiving somidobove may be limited by the amount of protein available at the small intestine.     

Comparison of somatotropin and growth hormone-releasing factor on milk yield, serum hormones, and energy status.

Holstein cows received 12 mg/d of growth hormone-releasing factor (continuous i.v. infusion, n = 5), 14 mg/d of bST (single daily i.m. injection, n = 8), or no treatment (controls, n = 8) for 60 d. Compared with controls (31.6 kg/d), bST and growth hormone-releasing factor increased milk yield to 34.2 and 37.0 kg/d, respectively. The increase in milk yield induced by the growth hormone-releasing factor was greater than that for bST. Milk yield was not different among groups following cessation of treatment. Milk energy output was 24.2 Mcal/d in controls, and growth hormone-releasing factor increased milk energy output to 28.5 Mcal/d. Milk energy output of cows receiving bST was 26.1 Mcal/d. Growth hormone-releasing factor increased DMI (23.2 kg/d) over that of controls (21.1 kg/d), whereas bST (21.5 kg/d) did not. Relative to controls, bST increased averaged daily serum somatotropin from 1.3 to 7.6 ng/ml and insulin-like growth factor-I from 67.5 to 116.0 ng/ml. Relative to bST, growth hormone-releasing factor increased serum somatotropin to 16.3 ng/ml and insulin-like growth factor-I to 202.6 ng/ml. Relative to control (115.8 meq/dl) and bST (158.1 meq/dl), growth hormone-releasing factor increased plasma NEFA (230.3 meq/dl). During treatment, calculated energy balance was negative for cows receiving growth hormone-releasing factor but positive for bST and control cows. Milk composition, body condition score, BW, and apparent digestibility of DM were not different among treatments. We conclude that i.v. infusion of 12 mg/d mg of growth hormone-releasing factor has greater galactopoietic activity than i.m. injections of 14 mg/d of bST.(ABSTRACT TRUNCATED AT 250 WORDS)     

Effect of somatotropin on kinetics of nonesterified fatty acids and partition of energy, carbon, and nitrogen in lactating dairy cows

The utilization of energy, carbon, and nitrogen, and irreversible loss rates of nonesterified fatty acids were examined in lactating cows during treatment with bovine somatotropin. Six multiparous Holstein cows at approximately 62 d postpartum received daily intramuscular injections of somatotropin (29.4 mg/d) or excipient during two 21-d treatment periods in a crossover experimental design. Milk yield was increased 11% (37.1 versus 41.3 kg/d), whereas intake and digestibility of DM, energy, nitrogen, and carbon were not affected. Cows remained near zero net energy balance during both treatments (1.31 versus -1.52 Mcal/d for control and somatotropin, respectively). The major effect of somatotropin was to partition net energy into milk while tissue energy accretion was reduced. Postabsorptive use of nitrogen and carbon was altered by somatotropin as reflected by greater secretion in milk. Urinary losses of nitrogen and tissue use of carbon were reduced. Plasma concentrations and irreversible loss rates of nonesterified fatty acids did not differ between treatments. Somatotropin treatment of lactating cows results in partitioning of nutrients away from tissue deposition toward milk synthesis. The extent to which different metabolic processes are altered depends upon the energy balance of the somatotropin-treated animal.     

Milk yield of dairy cows receiving somatotropin (somavubove) daily with periodic 14-day interruption.

Thirty multiparous (cows) and 15 primiparous (heifers) lactating Holstein cattle were used in a 112-d study to examine the effects of pattern of administration of recombinantly derived bST on 3.5% FCM yield. Ten cows and 5 heifers each received either no injection (controls), 14 mg of bST daily, or four repetitions of 14 mg of bST/d for 14 d followed by 14 d of no injection (intermittent bST). Because there was an interaction between treatment groups and parity, analyses were performed separately for cows and heifers. All cows and heifers produced more FCM when given bST than controls. Comparing FCM only during the last 7 d of each period of injection for the intermittent bST group with contemporary daily injected cattle indicated that cows produced equivalent amounts of milk at those times, whereas heifers given daily bST produced 3.4 kg/d more than intermittently injected animals. Furthermore, over each of the four repetitive periods, cows and heifers given daily or intermittent bST responded similarly, although heifers given continuous bST produced more FCM than the intermittent group during each of periods 2 through 4. We conclude that daily administration of bST lends itself to dosing termination during established lactation with concomitant decline of FCM; resumption of bST allows milk yields of cows to achieve levels comparable with those prior to short-term interruption.     

Effect of somidobove sustained release administration on the lactation performance of dairy cows

Lactation performance was determined on 190 multiparous Holsteins from five herds supplemented with 0, 320, 640, or 960 mg of somidobove every 28 d. The experiment consisted of 21 d of pretreatment and treatment periods of various lengths, depending upon stage of lactation of animals at first administration. Somidobove beginning in early (28 to 45 d in milk), mid (111 to 166 d in milk), or late (166 to 334 d in milk) stages of lactation consisted of 9, 6, or 3 administrations. Milk and 3.5% FCM yields were increased by each dose of somidobove in all stages. Milk composition and dry matter and energy intakes were similar among treatments within stage. Milk to DMI ratio and milk energy to net energy intake ratio were improved by somidobove. Gain was positive for all treatments, but less in somidobove-supplemented cows. Lower body weight and condition score at the completion of somidobove treatment resulted. For early cows, days to first estrus and days to first breeding were similar; however, total number of inseminations for cows receiving somidobove was twofold greater than control, resulting in a longer calving interval. Results demonstrated efficacy of somidobove administered every 28 d to lactating dairy cattle for increased milk yield.     

Effects of long daily photoperiod and bovine somatotropin (Trobest) on milk yield in cows.

Bovine somatotropin (bST) and exposure to long daily photoperiod increase milk yield of dairy cattle. We tested the hypothesis that long daily photoperiod and bST treatment would increase milk yield in an additive manner in lactating cows. At winter solstice, 40 lactating cows were started on a 140-d experiment; cows were greater than 70 d in milk (DIM) and were balanced for uniformity of DIM and milk yield within parity. Cows were randomly assigned to one of four treatments (10/treatment): 1) natural photoperiod, 2) natural photoperiod + bST (14 mg/d Trobest i.m.), 3) long daily photoperiod (18 h of light and 6 h of darkness/d), or 4) long daily photoperiod + bST. Long daily photoperiod increased fat-corrected milk (FCM) yield 1.9 kg/d versus natural photoperiod. Treatment with bST increased FCM 5.7 kg/d versus natural photoperiod, and long daily photoperiod + bST increased FCM 5.8 kg/d versus long daily photoperiod. Long daily photoperiod + bST was additive, increasing FCM 7.7 kg/d versus natural photoperiod. Serum somatotropin increased with bST, but not photoperiod, and bST increased serum insulin-like growth factor-I. Long daily photoperiod tended to increase prolactin; bST had no effect. Long daily photoperiod + bST increased dry matter intake (DMI) relative to natural photoperiod and natural photoperiod + bST; long daily photoperiod increased DMI relative to natural photoperiod + bST. Photoperiod had no effect on net energy balance; however, bST decreased net energy balance. Generally, body weight and milk composition did not differ among treatments. In conclusion, combination of bST with long-daily photoperiod tended to amplify the increases in milk yield observed with either treatment individually.     

Milk production and feed intake of Holstein cows given short (30-d) or normal (60-d) dry periods

Eighty-four Holstein cows were utilized to evaluate effects of dry period (60 d vs. 30 d), with or without estradiol cypionate (ECP) injections to accelerate mammary involution, on prepartum and postpartum dry matter intake (DMI), body weight (BW), body condition score (BCS), and subsequent milk yield (MY). Treatments were arranged in a 3 x 2 x 2 factorial design that included dry period (30 d dry, 30 d dry + ECP, and 60 d dry), prepartum and postpartum bovine somatotropin (bST; 10.2 mg/d), and prepartum anionic or cationic diets. To accelerate mammary involution, ECP (15 mg) was injected intramuscularly at dry-off. No interaction of bST or prepartum diet with dry period length was detected on BW, BCS, or MY. No significant effects of dry period length on prepartum DMI, BW, or BCS were detected. Cows with shorter dry periods maintained postpartum BCS better and tended to have greater DMI immediately postpartum. Mean daily yields of milk for dry period groups did not differ during overall lactation period (1 to 21 wk). Injection of ECP at the onset of the 30-d dry period did not affect MY. No significant differences due to dry period length were detected for milk, 3.5% FCM, or SCM yields during first 10 wk of lactation. Data indicated that a short dry period protocol can be used as a management tool with no loss in the subsequent milk production of dairy cows.     

Milk lipoprotein lipase activity during long-term administration of recombinant bovine somatotropin

The effect of long-term administration of recombinant bovine somatotropin to dairy cows on milk lipoprotein lipase activity was investigated. Recombinant bovine somatotropin was administered daily to 32 cows (8/treatment). Treatments were 0 (control), 12.5, 25.0, and 50.0 mg/d or recombinant bovine somatotropin administered in once daily intramuscular injections. Treatments began at 28 to 35 d of lactation and continued until 294 d of lactation. Recombinant bovine somatotropin treatments had no significant effect on milk lipoprotein lipase activity; enzyme activity for each treatment was 97.87, 108.96, 99.96, and 92.43 units/ml of milk, respectively. A significant effect of the stage of lactation was unrelated to recombinant bovine somatotropin administration. Enzyme activity peaked at approximately 20 wk of the treatment or 25 wk postpartum. These results indicate that long-term administration of recombinant bovine somatotropin does not alter the processes that lead to lipoprotein lipase activity in milk.     

The effect of uncouplers of oxidative phosphorylation on the feeding behavior of lactating dairy cows

Our objective was to determine the effects of uncouplers of oxidative phosphorylation on feeding behavior of lactating dairy cows. We hypothesized that uncouplers of oxidative phosphorylation would increase meal size and meal length and performed 2 experiments to test our hypothesis. In experiment 1, 4 late-lactation cows (345 ± 48.4 d in milk; mean ± SD) were administered a daily intrajugular injection of either 10 mg/kg of BW^0.75 of 2,4-dinitrophenol methyl ether (DNPME) and propylene carbonate or propylene carbonate (control; CON) in a crossover design with 2-d periods. In experiment 2, 8 early-lactation cows (11.3 ± 0.89 d in milk) were administered a daily intrajugular injection via jugular catheter of either 50 mg/kg of BW of sodium salicylate (SAL) and saline or saline (control; CON) in a crossover design with 1-d periods. Feeding behavior was recorded by a computerized data acquisition system and analyzed for the first 4 h after access to feed within 15 min of treatment for both experiments. Neither DNPME nor SAL affected meal size over the first 4 h after access to feed. However, DNPME increased meal length by 6.4 min (26.3 vs. 19.9 min) and tended to decrease the number of meals (2.55 vs. 2.78 meals/4 h) over the first 4 h after access to feed compared with CON. Both DNPME and SAL decreased eating rate over the first 4 h after access to feed compared with their respective controls (0.10 vs. 0.12 kg/min for DNPME vs. CON; 0.06 vs. 0.07 kg/min for SAL vs. CON). Lack of treatment effects on meal size may have been caused by increased rate of oxidation of fuels compensating for the disruption of oxidative phosphorylation.     

Conception rate, growth, and lactation of dairy heifers treated with recombinant somatotropin

Eighty Holstein heifers (295 kg; 13 to 16 mo of age) were allotted to two treatments in a completely random design experiment to determine the effect of daily injections of recombinant bovine somatotropin on conception, growth, and subsequent lactation. Heifers were treated with either 41.2 mg of bovine somatotropin or saline daily for 5 mo. Breeding was initiated 2 mo after the start of bovine somatotropin or saline treatment. Conception rates and number of services per conception did not differ between treatments. During the injection period, heifers treated with bovine somatotropin gained .18 kg/d faster than control heifers. During the 5 mo following the treatment period, control heifers gained .12 kg/d faster than the heifers that had received bovine somatotropin so that at the end of this 10-mo period weights of heifers in the 2 groups were similar. The heifers treated with bovine somatotropin had a greater increase in both hip height and pelvic size compared with control heifers during the 5-mo treatment period. Calving difficulty scores were similar between treatments. Treatment with bovine somatotropin prior to and during breeding of these heifers did not affect milk yield after first calving compared with control heifers.